Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-03-07FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for zoledronic acid submitted by Mylan Institutional LLC.
-
CLINICAL_TRIALS trial_result · 2023-03-07Clinical Trial Update: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial exploring APG-2575 as monotherapy or in combination with lenalidomide or DXMS in relapsed/refractory multiple myeloma.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic lenalidomide (LENALIDOMIDE) under ANDA211846.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Lenalidomide from Mylan Pharmaceuticals as an original application (ANDA), marking the approval of a generic lenalidomide.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Aurobindo Pharma Limited)
FDA approved Lenalidomide as a generic product under an original application from Aurobindo Pharma Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved a generic lenalidomide product for Teva under ANDA201452, expanding access to lenalidomide formulations.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved Alvogen, Inc.'s original Abbreviated New Drug Application for a generic lenalidomide product (ANDA 210480).
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
FDA approves a generic lenalidomide product from Exelan Pharmaceuticals under an original application. The drug is indicated for several hem…
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) [Phase 2]
Phase 2 MATCH subprotocol Z1F investigates copanlisib for cancers with PIK3CA mutations. Results (posted 2023-02-28) pertain to participants…
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant [Phase 2]
Phase 2 trial comparing generic pegfilgrastim to brand-name pegfilgrastim for neutrophil recovery after autologous transplantation.
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating cobimetinib alone or with venetoclax, with or without atezolizumab, in relapsed/refractory multiple myeloma; stud…
-
CLINICAL_TRIALS trial_result · 2023-02-27Clinical Trial Update: Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM [Phase 2]
A Phase 2 clinical trial evaluating selinexor in combination with an immunomodulator (thalidomide/pomalidomide/lenalidomide) for relapsed/re…
-
CLINICAL_TRIALS trial_result · 2023-02-24Clinical Trial Update: A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) [Phase 1, Phase 2]
Phase 1/2 trial evaluating TAK-079 as a single-agent subcutaneous therapy for relapsed/refractory multiple myeloma completed with posted res…
-
CLINICAL_TRIALS trial_result · 2023-02-23Clinical Trial Update: Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma [Phase 3]
Phase 3 trial assessing lenalidomide plus dexamethasone in multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2023-02-23Clinical Trial Update: Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating safety and efficacy of anti-GPRC5D CAR-T cells for relapsed/refractory multiple myeloma. Details on re…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma [Phase 2]
Phase 2 clinical trial update for KRN125 in patients with multiple myeloma and malignant lymphoma has been completed.
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating the safety and efficacy of durvalumab in combination with daratumumab for relapsed/refractory multiple myeloma; stu…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 clinical trial update for a BCMA CAR-T cell therapy in newly diagnosed multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-02-17Clinical Trial Update: Prolonged Protection From Bone Disease in Multiple Myeloma [Phase 4]
Phase 4 clinical trial update reporting prolonged protection from bone disease in patients with multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-02-13Clinical Trial Update: Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients [Phase 3]
A Phase 3 multinational trial comparing isatuximab, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in relapsed/refracto…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) [Phase 2]
Phase 2 study of the IDd regimen (ixazomib, daratumumab, dexamethasone) in relapsed/refractory multiple myeloma has completed enrollment and…
-
FDA approval · 2023-02-08FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical Industries' Lenalidomide Original Application, granting a generic lenalidomide product for multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention [Phase 3]
Phase 3 trial comparing Tacrolimus plus mini-methotrexate versus Tacrolimus plus methotrexate for graft-versus-host disease prevention has c…
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: PVd Versus Vd in NDMM Patients With RI [Phase 2]
A Phase 2 trial comparing PVd versus Vd in newly diagnosed multiple myeloma patients with renal impairment is ongoing; status is currently U…
-
CLINICAL_TRIALS trial_result · 2023-01-23Clinical Trial Update: Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis [Phase 2]
Phase 2 trial of adoptive immunotherapy in relapsed hematological malignancies with early GVHD prophylaxis has completed enrollment and post…